Pfizer's Super Bowl 2025 Ad Featuring Young Cancer Survivor Sparks Mixed Reactions
Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will ...
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
PharmExec23h
FDA Approves Pfizer’s Adcetris for Relapsed or Refractory Large B-Cell Lymphoma
Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
Fierce Biotech1d
Corbus posts first US data on challenger to Pfizer’s ADC Padcev
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Pfizer and Astellas announce results from phase 3 EV-302 clinical trial
Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...
BioSpace2d
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
Fierce Biotech3d
Pfizer's investigational candidate combo cuts prostate cancer progression by 49% in phase 1
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
Pharmabiz11h
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Pfizer’s Adcetris combination regimen approved by FDA for r/r DLBCL
Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with ...
Benzinga.com12d
Pfizer Trial For Colorectal Cancer Treatment Shows Improved Survival In Late-Stage Study
Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF ...
Pharmabiz1d
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma
Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...